This Article Full Text Full Text (PDF) All Versions of this Article: 25/6/1128    most recent 01.ATV.0000158996.03867.72v1 Submit a response Alert me when this article is cited Alert me when eLetters are posted Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Hoenig, M. R. Articles by Campbell, J. H. Search for Related Content PubMed PubMed Citation Articles by Hoenig, M. R. Articles by Campbell, J. H. Related Collections Other Treatment Other Research

(Arteriosclerosis, Thrombosis, and Vascular Biology. 2005;25:1128.)
© 2005 American Heart Association, Inc.

Brief Reviews

Tissue-Engineered Blood Vessels

Alternative to Autologous Grafts?

Michel R. Hoenig; Gordon R. Campbell; Barbara E. Rolfe; Julie H. Campbell

From the Centre for Research in Vascular Biology, School of Biomedical Sciences, The University of Queensland, Brisbane, Queensland, Australia.

Correspondence to Professor Julie H. Campbell, Centre for Research in Vascular Biology, School of Biomedical Sciences, The University of Queensland, Brisbane, Queensland 4072, Australia. E-mail julie.campbell{at}uq.edu.au

Although vascular bypass grafting remains the mainstay for revascularization for ischemic heart disease and peripheral vascular disease, many patients do not have healthy vessels suitable for harvest. Thus, prosthetic grafts made of synthetic polymers were developed, but their use is limited to high-flow/low-resistance conditions because of poor elasticity, low compliance, and thrombogenicity of their synthetic surfaces. To fill this need, several laboratories have produced in vivo or in vitro tissue-engineered blood vessels using molds or prosthetic or biodegradable scaffolds, but each artificial graft has significant problems. Recently, conduits have been grown in the peritoneal cavity of the same animals in which they will be grafted, ensuring no rejection, in the short time of 2 to 3 weeks. Remodeling occurs after grafting such that the tissue is almost indistinguishable from native vessels. This conduit is derived from cells of bone marrow origin, opening new possibilities in vascular modeling and remodeling.

Several laboratories have produced tissue-engineered blood vessels using molds or prosthetic or biodegradable scaffolds, but each has significant problems. Recently, autologous vascular conduits, derived from cells of bone marrow origin, have been grown in the peritoneal cavity of animals. This technology opens new possibilities in vascular modeling and remodeling.

Key Words: artificial arteries • bypass grafts • myofibroblasts • tissue engineering • tissue scaffolds

This article has been cited by other articles:

				R. F. Padera Jr. and F. J. Schoen Pathology of Cardiac Surgery Card. Surg. Adult, January 1, 2008; 3(2008): 111 - 178. [Full Text]

				M. Lahtinen, P. Blomberg, G. Baliulis, F. Carlsson, H. Khamis, and V. Zemgulis In vivo h-VEGF165 gene transfer improves early endothelialisation and patency in synthetic vascular grafts Eur. J. Cardiothorac. Surg., March 1, 2007; 31(3): 383 - 390. [Abstract] [Full Text] [PDF]